JAAD Case Rep 2020 Dec 15;6(12):1286-1287. Epub 2020 Oct 15.
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
Ital J Dermatol Venerol 2021 Jul 20. Epub 2021 Jul 20.
Dermatology Section, Department of Medical, Surgical and Neurological Science, S. Maria alle Scotte Hospital, University of Siena, Siena, Italy -
Background: Sleep disturbances are common in patients with atopic dermatitis (AD). Considering their relevant burden on health, routine screening of sleep disturbances seems to be very useful in AD adults management. However, few studies have evaluated the association between sleep disturbances and AD in adults and real-life data are lacking. Read More
Ulster Med J 2021 May 8;90(2):70-76. Epub 2021 Jul 8.
Department of Dermatology, Royal Victoria Hospital, Belfast Health and Social Care Trust, BT12 6BA, Northern Ireland, UK.
Background: Dupilumab, a monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signalling is indicated in dermatology for the treatment of moderate-to-severe atopic dermatitis (AD) in adult and adolescent patients 12 years and older and severe AD in children 6-11 years, who are candidates for systemic therapy. Dupilumab received Early Access to Medicines Scheme (EAMS) approval for adults in March 2017.Objectives: The purpose of this study was to assess the efficacy outcomes of treatment with dupilumab in EAMS. Read More
Pediatr Dermatol 2021 Jul 16. Epub 2021 Jul 16.
Division of Dermatology and Dermatologic Surgery, Department of Internal Medicine, Dell Medical School at The University of Texas, Austin, TX, USA.
Common polygenic skin disorders, such as atopic dermatitis, may rarely present in a segmental or linear distribution due to cutaneous mosaicism. Only seven cases of superimposed linear atopic dermatitis have been reported to date. Here, we present a child with severe superimposed linear atopic dermatitis and highlight the first successful use of dupilumab in its treatment. Read More
Clin Pharmacol Ther 2021 Jul 16. Epub 2021 Jul 16.
Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.
Dupilumab demonstrated efficacy with an acceptable safety profile in two randomized, double-blind, placebo-controlled, parallel-group, phase III trials in adolescents (12-17 years; LIBERTY AD ADOL) and children (6-11 years; LIBERTY AD PEDS) with atopic dermatitis (AD) treated for 16 weeks. Here, we present the pharmacokinetic profiles and exposure-response relationships of dupilumab that guided the posology in these populations. A total of 251 adolescent patients with moderate-to-severe AD were randomized to subcutaneous dupilumab monotherapy every 2 weeks (q2w) (200 mg q2w, baseline weight <60 kg; 300 mg q2w, ≥60 kg), dupilumab 300 mg every 4 weeks (q4w) (non-weight tiered), or placebo; 367 children with severe AD were randomized to dupilumab q2w (100 mg q2w, baseline weight <30 kg; 200 mg q2w, ≥30 kg), dupilumab 300 mg q4w, or placebo. Read More
Dermatol Ther 2021 Jul 9:e15059. Epub 2021 Jul 9.
Department of Health Sciences, University of Catanzaro "Magna Graecia", Catanzaro, Italy.
Ocular comorbidities are more frequent in patients with severe atopic dermatitis (AD) compared to general population. Dupilumab, a fully human monoclonal antibody that prevents the signaling of interleukin (IL)-4 and IL-13, is reported to be efficacious and safe for the treatment of moderate-to-severe AD, asthma, and chronic sinusitis. However, conjunctivitis was the most common side effect observed both in clinical trials and real-life studies in atopic patients. Read More